Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01736696

Enrollment

Registered

2012-11-29

Start date

2002-11-30

Completion date

2004-04-30

Last updated

2013-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunomodulation, Psoriasis

Keywords

Psoriasis, PASI, plaques, skin biopsy, immunomodulation

Brief summary

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

Interventions

DRUGtofacitinib

5 mg BID For 13 days and once on Day 14

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male and/or female subjects between the ages of 18 and 65 years, inclusive, with active psoriasis lesion(s). * Subjects should be healthy with the exception of psoriasis, where healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination. Blood pressure must be \< 140/89. Body Mass Index (BMI) between 18-36 kg/m2, inclusive; and a total body weight \>50 kg (110 lbs) * The following laboratory variables must be no more than 10% below the lower limit of the normal reference range: RBC, hemoglobin, hematocrit, WBC, absolute neutrophil count. The absolute lymphocyte count must be greater than or equal to the lower limit of the reference range. Values for AST, ALT, bilirubin and alkaline phosphatase must be no more than 10% above the upper limit of the normal reference range. Values for total cholesterol and LDL must be no more than 20% above the upper limit of the normal reference range except for subjects being treated for hyperlipidemia. Normal glomerular filtration rate (\> 80 mL/min).

Exclusion criteria

* Subjects with evidence or history of clinically significant hematological, renal, urological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disorder. * Subjects with controlled essential hypertension and/or hyperlipidemia may be eligible for the study provided that any medications that are administered. * Screening 12-lead ECG demonstrating at least one of the following: heart rate \> 100 bpm, QRS \>120 msec, QTc \> 430 msec (males), QTc \> 450 msec (females) or PR \> 220 msec. * Abnormal chest radiographs including, but not limited to, evidence of past or present tuberculosis infection. History of tuberculosis without treatment and/or positive tuberculin reaction without known vaccination with BCG. * Subjects with a history of tumors with the exception of adequately treated basal cell carcinoma of the skin.

Design outcomes

Primary

Measure	Time frame	Description
Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)	Day 14	EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.
Change From Baseline in Reticulocyte Count at Day 7	Baseline (Within 7 days prior to Day 1), Day 7	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 10	Baseline (Within 7 days prior to Day 1), Day 10	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 15	Baseline (Within 7 days prior to Day 1), Day 15	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 21	Baseline (Within 7 days prior to Day 1), Day 21	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 28	Baseline (Within 7 days prior to Day 1), Day 28	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 42	Baseline (Within 7 days prior to Day 1), Day 42	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function	Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42	—
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1	Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.
Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1	AUCtau = area under the curve from time zero to end of dosing interval.
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14	AUCtau = area under the curve from time zero to end of dosing interval.
Maximum Observed Plasma Concentration (Cmax) at Day 1	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1	—
Maximum Observed Plasma Concentration (Cmax) at Day 14	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14	—
Accumulation Ratio (R0)	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14	Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Baseline, 1 hr post-dose on Day 1	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Baseline, hr 0 on Day 2	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Baseline, hr 0 on Day 4	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Baseline, hr 0 on Day 7	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Baseline, hr 0 on Day 10	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Baseline; hr 0, 8 hr post-dose on Day 14	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Baseline, Hour 0 on Day 18	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Baseline, hr 0 on Day 21	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Baseline, hr 0 on Day 28	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Baseline, hr 0 on Day 42	Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Change From Baseline in Immune Cell Function at Day 14	Baseline (Within 7 days prior to Day 1), Day 14	The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.
Change From Baseline in Reticulocyte Count at Day 2	Baseline (Within 7 days prior to Day 1), Day 2	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Change From Baseline in Reticulocyte Count at Day 4	Baseline (Within 7 days prior to Day 1), Day 4	Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Secondary

Measure	Time frame	Description
Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	Baseline (Within 7 days prior to Day 1) up to Day 14	Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).
Gene Expression in Psoriatic Plaque Biopsies	Day 14	Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.
Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline (within 7 days prior to Day 1), Day 14	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.
Number of Participants With Keratin 16 (K16) Expression	Baseline (within 7 days prior to Day 1) up to Day 14	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.
Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression	Baseline (within 7 days prior to Day 1) up to Day 14	Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.
Gene Expression in Peripheral Blood	Day 14	Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).
Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Baseline (Within 7 days prior to Day 1) up to Day 14	Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.

Countries

United States

Participant flow

Participants by arm

Arm	Count
CP-690,550 5 mg (Cohort 1) CP-690,550 5 milligram (mg) oral powder for constitution (OPC) twice daily for 13 days and single oral dose on Day 14.	5
CP-690,550 10 mg (Cohort 2) CP-690,550 10 mg OPC twice daily for 13 days and single oral dose on Day 14.	5
CP-690,550 20 mg (Cohort 3) CP-690,550 20 mg OPC twice daily for 13 days and single oral dose on Day 14.	10
CP-690,550 30 mg (Cohort 4) CP-690,550 30 mg OPC twice daily for 13 days and single oral dose on Day 14.	9
CP-690,550 60 mg (Cohort 5) CP-690,550 60 mg tablets orally once daily up to Day 14.	9
CP-690,550 50 mg (Cohort 6) CP-690,550 50 mg tablets orally twice daily for 13 days and single oral dose on Day 14.	8
Placebo Placebo matched to CP-690,550 for 13 days and single oral dose on Day 14.	13
Total	59

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006
Overall Study	Withdrawal by Subject	0	0	1	0	0	0	0

Baseline characteristics

Characteristic	CP-690,550 5 mg (Cohort 1)	CP-690,550 10 mg (Cohort 2)	CP-690,550 20 mg (Cohort 3)	CP-690,550 30 mg (Cohort 4)	CP-690,550 60 mg (Cohort 5)	CP-690,550 50 mg (Cohort 6)	Placebo	Total
Age Continuous	40.2 years STANDARD_DEVIATION 12.8	43.8 years STANDARD_DEVIATION 7.4	39.6 years STANDARD_DEVIATION 11.1	44.6 years STANDARD_DEVIATION 11.1	46.9 years STANDARD_DEVIATION 10.2	47.1 years STANDARD_DEVIATION 9.7	44.4 years STANDARD_DEVIATION 10.4	43.9 years STANDARD_DEVIATION 10.3
Sex: Female, Male Female	3 Participants	2 Participants	3 Participants	1 Participants	4 Participants	4 Participants	5 Participants	22 Participants
Sex: Female, Male Male	2 Participants	3 Participants	7 Participants	8 Participants	5 Participants	4 Participants	8 Participants	37 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	0 / 5	1 / 5	3 / 10	1 / 9	2 / 9	2 / 8	2 / 13
serious Total, serious adverse events	0 / 5	1 / 5	0 / 10	0 / 9	0 / 9	0 / 8	0 / 13

Outcome results

Primary

Accumulation Ratio (R0)

Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14

Population: Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Accumulation Ratio (R0)	0.974 Ratio	Standard Deviation 0.181
CP-690,550 10 mg (Cohort 2)	Accumulation Ratio (R0)	1.22 Ratio	Standard Deviation 0.203
CP-690,550 20 mg (Cohort 3)	Accumulation Ratio (R0)	1.22 Ratio	Standard Deviation 0.389
CP-690,550 30 mg (Cohort 4)	Accumulation Ratio (R0)	1.62 Ratio	Standard Deviation 0.343
CP-690,550 60 mg (Cohort 5)	Accumulation Ratio (R0)	1.16 Ratio	Standard Deviation 0.27
CP-690,550 50 mg (Cohort 6)	Accumulation Ratio (R0)	1.14 Ratio	Standard Deviation 0.176

Primary

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1

AUCtau = area under the curve from time zero to end of dosing interval.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	161 nanogramhour/milliliter (nghr/mL)	Standard Deviation 86.1
CP-690,550 10 mg (Cohort 2)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	349 nanogramhour/milliliter (nghr/mL)	Standard Deviation 34.7
CP-690,550 20 mg (Cohort 3)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	732 nanogramhour/milliliter (nghr/mL)	Standard Deviation 232
CP-690,550 30 mg (Cohort 4)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	860 nanogramhour/milliliter (nghr/mL)	Standard Deviation 235
CP-690,550 60 mg (Cohort 5)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	2120 nanogramhour/milliliter (nghr/mL)	Standard Deviation 837
CP-690,550 50 mg (Cohort 6)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1	1720 nanogramhour/milliliter (nghr/mL)	Standard Deviation 453

Primary

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14

AUCtau = area under the curve from time zero to end of dosing interval.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	154 ng*hr/mL	Standard Deviation 80.3
CP-690,550 10 mg (Cohort 2)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	422 ng*hr/mL	Standard Deviation 49.5
CP-690,550 20 mg (Cohort 3)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	850 ng*hr/mL	Standard Deviation 216
CP-690,550 30 mg (Cohort 4)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	1350 ng*hr/mL	Standard Deviation 308
CP-690,550 60 mg (Cohort 5)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	2600 ng*hr/mL	Standard Deviation 1580
CP-690,550 50 mg (Cohort 6)	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14	1780 ng*hr/mL	Standard Deviation 501

Primary

Change From Baseline in Immune Cell Function at Day 14

The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.

Time frame: Baseline (Within 7 days prior to Day 1), Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n' = participants evaluable for this measure at specified time points for each arm group respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	11.50 ng/mL	Standard Deviation 9.9
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	9.50 ng/mL	Standard Deviation 2.8
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	222.75 ng/mL	Standard Deviation 157.3
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	92.75 ng/mL	Standard Deviation 120.6
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	95.80 ng/mL	Standard Deviation 135
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	205.40 ng/mL	Standard Deviation 143.1
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	10.60 ng/mL	Standard Deviation 3.2
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	5.60 ng/mL	Standard Deviation 11.4
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	16.30 ng/mL	Standard Deviation 6.6
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	155.11 ng/mL	Standard Deviation 168
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	429.00 ng/mL	Standard Deviation 115.3
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	0.44 ng/mL	Standard Deviation 8.9
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	406.11 ng/mL	Standard Deviation 171.6
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	16.44 ng/mL	Standard Deviation 10.2
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	90.11 ng/mL	Standard Deviation 125.9
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	0.33 ng/mL	Standard Deviation 10.6
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	210.56 ng/mL	Standard Deviation 104.1
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	1.67 ng/mL	Standard Deviation 15.4
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	14.11 ng/mL	Standard Deviation 8.3
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	118.78 ng/mL	Standard Deviation 88.2
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	0.29 ng/mL	Standard Deviation 13.1
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	7.14 ng/mL	Standard Deviation 5.9
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	61.21 ng/mL	Standard Deviation 124.7
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	252.50 ng/mL	Standard Deviation 146.3
Placebo	Change From Baseline in Immune Cell Function at Day 14	Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)	16.00 ng/mL	Standard Deviation 12.4
Placebo	Change From Baseline in Immune Cell Function at Day 14	Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)	301.88 ng/mL	Standard Deviation 152.9
Placebo	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)	26.81 ng/mL	Standard Deviation 66.6
Placebo	Change From Baseline in Immune Cell Function at Day 14	Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)	1.46 ng/mL	Standard Deviation 11.2

Primary

Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14

Time frame: Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	-14.53 msec	Standard Deviation 11.39
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	374.80 msec	Standard Deviation 28.95
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	360.40 msec	Standard Deviation 28.03
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	11.00 msec	Standard Deviation 12
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	-0.33 msec	Standard Deviation 14.08
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	367.70 msec	Standard Deviation 30.28
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	372.81 msec	Standard Deviation 27.83
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	7.22 msec	Standard Deviation 16.38
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	-9.70 msec	Standard Deviation 13.15
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	383.41 msec	Standard Deviation 19.25
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	367.50 msec	Standard Deviation 22.12
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	-0.79 msec	Standard Deviation 17.48
Placebo	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Change at HPD 0 on Day 14	-7.08 msec	Standard Deviation 16.21
Placebo	Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14	Baseline for HPD 0	364.03 msec	Standard Deviation 20.96

Primary

Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1

Population: Analysis population included all participants who met the eligibility criteria. Here, the 'n' is signifying those participants who were evaluable for this measure at the specified time point for each arm group.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	371.73 msec	Standard Deviation 31.5
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-6.27 msec	Standard Deviation 19.05
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	351.27 msec	Standard Deviation 22.9
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-2.60 msec	Standard Deviation 5.27
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	372.63 msec	Standard Deviation 22.54
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-4.15 msec	Standard Deviation 17.9
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	370.11 msec	Standard Deviation 25.7
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	0.15 msec	Standard Deviation 9.79
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	379.78 msec	Standard Deviation 24.93
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-3.22 msec	Standard Deviation 19.73
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	363.08 msec	Standard Deviation 31.21
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-2.88 msec	Standard Deviation 14.01
Placebo	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Baseline for HPD 12 (n=5,5,10,9,9,8,13)	361.54 msec	Standard Deviation 16.29
Placebo	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1	Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)	-1.36 msec	Standard Deviation 13.6

Primary

Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14

Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	-13.47 msec	Standard Deviation 12.76
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	8.00 msec	Standard Deviation 8.48
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	-10.52 msec	Standard Deviation 10.63
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	0.81 msec	Standard Deviation 13.99
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	-7.44 msec	Standard Deviation 22.73
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	-0.63 msec	Standard Deviation 23.46
Placebo	Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14	-4.82 msec	Standard Deviation 15.31

Primary

Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1

Time frame: 8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	Baseline for HPD 16	377.15 msec	Standard Deviation 19.5
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	Change at HPD 16 on Day 1	11.19 msec	Standard Deviation 19.98
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	Baseline for HPD 16	345.44 msec	Standard Deviation 18.77
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1	Change at HPD 16 on Day 1	13.11 msec	Standard Deviation 7.26

Primary

Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame: 23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	372.20 millisecond (msec)	Standard Deviation 34.3
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	-6.33 millisecond (msec)	Standard Deviation 25.91
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	348.47 millisecond (msec)	Standard Deviation 23.52
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	15.73 millisecond (msec)	Standard Deviation 9.04
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	369.40 millisecond (msec)	Standard Deviation 19.47
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	-6.33 millisecond (msec)	Standard Deviation 21.67
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	375.74 millisecond (msec)	Standard Deviation 24.65
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	2.70 millisecond (msec)	Standard Deviation 14.54
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	383.96 millisecond (msec)	Standard Deviation 18.1
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	1.63 millisecond (msec)	Standard Deviation 14.09
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	371.29 millisecond (msec)	Standard Deviation 28.33
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	-2.79 millisecond (msec)	Standard Deviation 13.28
Placebo	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Baseline for HPD 1	370.95 millisecond (msec)	Standard Deviation 18
Placebo	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1	Change at HPD 1 on Day 1	-4.21 millisecond (msec)	Standard Deviation 12.61

Primary

Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14

Time frame: 23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	-8.87 msec	Standard Deviation 12.12
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	22.27 msec	Standard Deviation 13.72
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	0.11 msec	Standard Deviation 12.55
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	2.81 msec	Standard Deviation 15.98
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	-0.96 msec	Standard Deviation 14.63
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	0.71 msec	Standard Deviation 20.43
Placebo	Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14	-12.87 msec	Standard Deviation 17.82

Primary

Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	369.67 msec	Standard Deviation 33.78
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-0.40 msec	Standard Deviation 26.39
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	350.27 msec	Standard Deviation 20.76
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	9.80 msec	Standard Deviation 13.71
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	372.87 msec	Standard Deviation 21.1
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-6.90 msec	Standard Deviation 22.22
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	377.48 msec	Standard Deviation 24.26
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-0.15 msec	Standard Deviation 12.82
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	387.00 msec	Standard Deviation 18.81
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-0.07 msec	Standard Deviation 9.4
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	374.00 msec	Standard Deviation 26.75
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-1.58 msec	Standard Deviation 13.66
Placebo	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Baseline for HPD 2	369.87 msec	Standard Deviation 17.53
Placebo	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1	Change at HPD 2 on Day 1	-2.05 msec	Standard Deviation 16.76

Primary

Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14

Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria.'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	-3.80 msec	Standard Deviation 12.18
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	18.67 msec	Standard Deviation 11.15
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	-3.93 msec	Standard Deviation 13.21
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	6.89 msec	Standard Deviation 13.98
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	-3.81 msec	Standard Deviation 17.18
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	2.46 msec	Standard Deviation 22.04
Placebo	Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14	-12.28 msec	Standard Deviation 19.35

Primary

Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	373.73 msec	Standard Deviation 31.71
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	-4.53 msec	Standard Deviation 23.17
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	348.07 msec	Standard Deviation 23.34
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	11.53 msec	Standard Deviation 12.32
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	373.20 msec	Standard Deviation 21.78
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	2.19 msec	Standard Deviation 20.98
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	373.15 msec	Standard Deviation 20.46
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	2.96 msec	Standard Deviation 17.94
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	381.44 msec	Standard Deviation 20.02
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	7.74 msec	Standard Deviation 14.69
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	381.17 msec	Standard Deviation 26.96
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	-8.17 msec	Standard Deviation 14.32
Placebo	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Baseline for HPD 4 (n=5,5,10,9,9,8,13)	368.00 msec	Standard Deviation 18.04
Placebo	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1	Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)	-2.82 msec	Standard Deviation 10.82

Primary

Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14

Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	-13.80 msec	Standard Deviation 15.37
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	6.53 msec	Standard Deviation 7.81
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	-8.41 msec	Standard Deviation 7.25
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	18.96 msec	Standard Deviation 18.55
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	9.59 msec	Standard Deviation 10.7
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	-4.79 msec	Standard Deviation 21.58
Placebo	Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14	-8.46 msec	Standard Deviation 21.09

Primary

Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1

Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	364.13 msec	Standard Deviation 36
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-1.27 msec	Standard Deviation 15.93
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	356.73 msec	Standard Deviation 25.62
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-6.60 msec	Standard Deviation 10.71
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	366.90 msec	Standard Deviation 22.02
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-3.96 msec	Standard Deviation 18.54
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	374.56 msec	Standard Deviation 22.73
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-3.44 msec	Standard Deviation 12.75
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	378.15 msec	Standard Deviation 23.91
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	7.67 msec	Standard Deviation 16.08
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	372.25 msec	Standard Deviation 28.29
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-9.83 msec	Standard Deviation 15.12
Placebo	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Baseline for HPD 8 (n=5,5,10,9,9,8,13)	367.56 msec	Standard Deviation 17.95
Placebo	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1	Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)	-9.03 msec	Standard Deviation 11.52

Primary

Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14

Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-9.33 msec	Standard Deviation 11.31
CP-690,550 10 mg (Cohort 2)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-0.53 msec	Standard Deviation 9.83
CP-690,550 20 mg (Cohort 3)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-6.15 msec	Standard Deviation 15.86
CP-690,550 30 mg (Cohort 4)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-1.96 msec	Standard Deviation 13.75
CP-690,550 60 mg (Cohort 5)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	4.85 msec	Standard Deviation 18.51
CP-690,550 50 mg (Cohort 6)	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-2.67 msec	Standard Deviation 23.28
Placebo	Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14	-12.36 msec	Standard Deviation 11.38

Primary

Change From Baseline in Reticulocyte Count at Day 10

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 10

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 10	-16.40 1000 cells/mm^3	Standard Deviation 29.5
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 10	-14.00 1000 cells/mm^3	Standard Deviation 18.3
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 10	16.00 1000 cells/mm^3	Standard Deviation 25.9
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 10	-18.22 1000 cells/mm^3	Standard Deviation 15.9
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 10	6.56 1000 cells/mm^3	Standard Deviation 17.5
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 10	-29.50 1000 cells/mm^3	Standard Deviation 21.5
Placebo	Change From Baseline in Reticulocyte Count at Day 10	-3.42 1000 cells/mm^3	Standard Deviation 38.8

Primary

Change From Baseline in Reticulocyte Count at Day 15

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 15

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 15	-24.00 1000 cells/mm^3	Standard Deviation 25.3
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 15	-11.40 1000 cells/mm^3	Standard Deviation 17.4
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 15	-8.56 1000 cells/mm^3	Standard Deviation 11.9
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 15	-42.22 1000 cells/mm^3	Standard Deviation 16.9
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 15	24.11 1000 cells/mm^3	Standard Deviation 16.8
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 15	-31.57 1000 cells/mm^3	Standard Deviation 25.9
Placebo	Change From Baseline in Reticulocyte Count at Day 15	-17.92 1000 cells/mm^3	Standard Deviation 28.4

Primary

Change From Baseline in Reticulocyte Count at Day 2

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 2

Population: Analysis population included all participants who met the eligibility criteria. 'n' = participants evaluable for this measure at specified time points for each arm group respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-6.60 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 21.3
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	124.00 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 30.6
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	94.00 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 36.9
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-2.00 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 13.7
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	81.50 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 20.1
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	20.00 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 16.1
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-17.67 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 24.2
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	95.22 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 14.3
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	80.56 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 24.4
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-10.88 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 19.7
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	79.75 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 25.8
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-3.75 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 11.1
Placebo	Change From Baseline in Reticulocyte Count at Day 2	Change at Day 2 (n=5,5,9,9,8,8,12)	-7.25 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 28.8
Placebo	Change From Baseline in Reticulocyte Count at Day 2	Baseline (n=5,5,10,9,9,8,13)	100.69 1000 cells/cubic millimeter (cells/mm^3)	Standard Deviation 46.2

Primary

Change From Baseline in Reticulocyte Count at Day 21

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 21

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 21	-13.40 1000 cells/mm^3	Standard Deviation 30.6
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 21	17.60 1000 cells/mm^3	Standard Deviation 11.5
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 21	44.22 1000 cells/mm^3	Standard Deviation 27.1
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 21	5.44 1000 cells/mm^3	Standard Deviation 14.4
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 21	40.25 1000 cells/mm^3	Standard Deviation 15.6
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 21	-9.17 1000 cells/mm^3	Standard Deviation 23.9
Placebo	Change From Baseline in Reticulocyte Count at Day 21	12.54 1000 cells/mm^3	Standard Deviation 40.2

Primary

Change From Baseline in Reticulocyte Count at Day 28

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 28

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 28	-16.20 1000 cells/mm^3	Standard Deviation 8.2
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 28	47.60 1000 cells/mm^3	Standard Deviation 14.8
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 28	49.56 1000 cells/mm^3	Standard Deviation 24
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 28	23.89 1000 cells/mm^3	Standard Deviation 23.5
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 28	21.75 1000 cells/mm^3	Standard Deviation 13.6
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 28	56.00 1000 cells/mm^3	Standard Deviation 24.1
Placebo	Change From Baseline in Reticulocyte Count at Day 28	-2.85 1000 cells/mm^3	Standard Deviation 32.5

Primary

Change From Baseline in Reticulocyte Count at Day 4

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 4

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 4	-14.00 1000 cells/mm^3	Standard Deviation 17.2
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 4	-7.60 1000 cells/mm^3	Standard Deviation 16.5
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 4	17.33 1000 cells/mm^3	Standard Deviation 26.6
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 4	-48.44 1000 cells/mm^3	Standard Deviation 13.3
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 4	-14.67 1000 cells/mm^3	Standard Deviation 16.4
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 4	-20.00 1000 cells/mm^3	Standard Deviation 14.9
Placebo	Change From Baseline in Reticulocyte Count at Day 4	-20.85 1000 cells/mm^3	Standard Deviation 41.2

Primary

Change From Baseline in Reticulocyte Count at Day 42

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 42

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 42	-4.60 1000 cells/mm^3	Standard Deviation 12.6
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 42	-7.00 1000 cells/mm^3	Standard Deviation 35.9
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 42	34.56 1000 cells/mm^3	Standard Deviation 30
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 42	-3.67 1000 cells/mm^3	Standard Deviation 12.5
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 42	-2.33 1000 cells/mm^3	Standard Deviation 21.9
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 42	22.50 1000 cells/mm^3	Standard Deviation 31.7
Placebo	Change From Baseline in Reticulocyte Count at Day 42	-18.00 1000 cells/mm^3	Standard Deviation 26.7

Primary

Change From Baseline in Reticulocyte Count at Day 7

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame: Baseline (Within 7 days prior to Day 1), Day 7

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Change From Baseline in Reticulocyte Count at Day 7	-3.40 1000 cells/mm^3	Standard Deviation 18.7
CP-690,550 10 mg (Cohort 2)	Change From Baseline in Reticulocyte Count at Day 7	6.40 1000 cells/mm^3	Standard Deviation 15.9
CP-690,550 20 mg (Cohort 3)	Change From Baseline in Reticulocyte Count at Day 7	17.11 1000 cells/mm^3	Standard Deviation 26.5
CP-690,550 30 mg (Cohort 4)	Change From Baseline in Reticulocyte Count at Day 7	-14.44 1000 cells/mm^3	Standard Deviation 13.6
CP-690,550 60 mg (Cohort 5)	Change From Baseline in Reticulocyte Count at Day 7	3.22 1000 cells/mm^3	Standard Deviation 20.6
CP-690,550 50 mg (Cohort 6)	Change From Baseline in Reticulocyte Count at Day 7	-30.38 1000 cells/mm^3	Standard Deviation 13.8
Placebo	Change From Baseline in Reticulocyte Count at Day 7	-1.38 1000 cells/mm^3	Standard Deviation 31.1

Primary

Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)

EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.

Time frame: Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)	2696 ng*hr/mL

Primary

Maximum Observed Plasma Concentration (Cmax) at Day 1

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Maximum Observed Plasma Concentration (Cmax) at Day 1	48.3 nanogram/milliliter (ng/mL)	Standard Deviation 24.5
CP-690,550 10 mg (Cohort 2)	Maximum Observed Plasma Concentration (Cmax) at Day 1	90.5 nanogram/milliliter (ng/mL)	Standard Deviation 20.4
CP-690,550 20 mg (Cohort 3)	Maximum Observed Plasma Concentration (Cmax) at Day 1	212 nanogram/milliliter (ng/mL)	Standard Deviation 62.3
CP-690,550 30 mg (Cohort 4)	Maximum Observed Plasma Concentration (Cmax) at Day 1	180 nanogram/milliliter (ng/mL)	Standard Deviation 53.1
CP-690,550 60 mg (Cohort 5)	Maximum Observed Plasma Concentration (Cmax) at Day 1	457 nanogram/milliliter (ng/mL)	Standard Deviation 88.2
CP-690,550 50 mg (Cohort 6)	Maximum Observed Plasma Concentration (Cmax) at Day 1	429 nanogram/milliliter (ng/mL)	Standard Deviation 99.1

Primary

Maximum Observed Plasma Concentration (Cmax) at Day 14

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

Arm	Measure	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Maximum Observed Plasma Concentration (Cmax) at Day 14	50.9 ng/mL	Standard Deviation 21.2
CP-690,550 10 mg (Cohort 2)	Maximum Observed Plasma Concentration (Cmax) at Day 14	87.7 ng/mL	Standard Deviation 13.2
CP-690,550 20 mg (Cohort 3)	Maximum Observed Plasma Concentration (Cmax) at Day 14	194 ng/mL	Standard Deviation 53.9
CP-690,550 30 mg (Cohort 4)	Maximum Observed Plasma Concentration (Cmax) at Day 14	225 ng/mL	Standard Deviation 43.9
CP-690,550 60 mg (Cohort 5)	Maximum Observed Plasma Concentration (Cmax) at Day 14	568 ng/mL	Standard Deviation 205
CP-690,550 50 mg (Cohort 6)	Maximum Observed Plasma Concentration (Cmax) at Day 14	403 ng/mL	Standard Deviation 133

Primary

Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.

Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants
Placebo	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcB	0 participants
Placebo	Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond	QTcF	0 participants

Primary

Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval

Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	1 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	2 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	1 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	1 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	3 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	3 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	1 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	2 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
Placebo	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:30 to <60msec	5 participants
Placebo	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:30 to <60msec	1 participants
Placebo	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcF,Maximum increase from baseline:>=60msec	0 participants
Placebo	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval	QTcB,Maximum increase from baseline:>=60msec	0 participants

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame: Baseline, 1 hr post-dose on Day 1

Population: Analysis population included all participants who met the eligibility criteria.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	-18.48 percent change	Standard Deviation 19.4
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	-7.58 percent change	Standard Deviation 11
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	11.22 percent change	Standard Deviation 27
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	-14.39 percent change	Standard Deviation 14.6
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-27.11 percent change	Standard Deviation 16.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	26.05 percent change	Standard Deviation 25.1
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-4.02 percent change	Standard Deviation 30.9
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	12.02 percent change	Standard Deviation 18.2
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	79.99 percent change	Standard Deviation 33.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	8.65 percent change	Standard Deviation 23.5
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	81.44 percent change	Standard Deviation 62.7
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	-4.29 percent change	Standard Deviation 15.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	1.17 percent change	Standard Deviation 17.7
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-10.30 percent change	Standard Deviation 18.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	8.90 percent change	Standard Deviation 22.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-8.23 percent change	Standard Deviation 10.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	18.34 percent change	Standard Deviation 21.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	74.07 percent change	Standard Deviation 38.6
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	5.99 percent change	Standard Deviation 15.6
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	12.44 percent change	Standard Deviation 17.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	8.38 percent change	Standard Deviation 23.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	104.44 percent change	Standard Deviation 85.8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	13.90 percent change	Standard Deviation 21.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-6.22 percent change	Standard Deviation 29.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	-1.13 percent change	Standard Deviation 19.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	8.54 percent change	Standard Deviation 10.7
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	12.83 percent change	Standard Deviation 14
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	25.44 percent change	Standard Deviation 14.6
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-0.66 percent change	Standard Deviation 9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	103.74 percent change	Standard Deviation 21.2
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD3	0.52 percent change	Standard Deviation 16.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD8	0.42 percent change	Standard Deviation 16.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD16/56	-9.72 percent change	Standard Deviation 18.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD4	1.35 percent change	Standard Deviation 18.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1	Change at Day 1: CD19	-6.46 percent change	Standard Deviation 22.4

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10

Time frame: Baseline, hr 0 on Day 10

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-16.73 percent change	Standard Deviation 29.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	6.86 percent change	Standard Deviation 20.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	5.70 percent change	Standard Deviation 18.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	5.34 percent change	Standard Deviation 20.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	24.06 percent change	Standard Deviation 26.9
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	16.87 percent change	Standard Deviation 34
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-25.53 percent change	Standard Deviation 41.4
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	34.97 percent change	Standard Deviation 38.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	8.76 percent change	Standard Deviation 35.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	4.13 percent change	Standard Deviation 39.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	76.05 percent change	Standard Deviation 71.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-16.22 percent change	Standard Deviation 22.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	0.68 percent change	Standard Deviation 35.4
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	14.50 percent change	Standard Deviation 50.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	12.47 percent change	Standard Deviation 49.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-33.38 percent change	Standard Deviation 27.2
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	28.77 percent change	Standard Deviation 40.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	36.76 percent change	Standard Deviation 43.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	38.22 percent change	Standard Deviation 43
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	79.94 percent change	Standard Deviation 69.2
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	14.61 percent change	Standard Deviation 54.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	16.81 percent change	Standard Deviation 62.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-21.99 percent change	Standard Deviation 36.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	11.30 percent change	Standard Deviation 50
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	63.64 percent change	Standard Deviation 180
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-37.90 percent change	Standard Deviation 24.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	16.85 percent change	Standard Deviation 32.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	12.61 percent change	Standard Deviation 30.6
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	7.87 percent change	Standard Deviation 20.1
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	84.57 percent change	Standard Deviation 109.7
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD8	-4.14 percent change	Standard Deviation 30.6
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD3	-3.69 percent change	Standard Deviation 27.9
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD19	-13.19 percent change	Standard Deviation 31.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD4	-4.52 percent change	Standard Deviation 27.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10	Change at Day 10: CD16/56	-10.82 percent change	Standard Deviation 31.3

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14

Time frame: Baseline; hr 0, 8 hr post-dose on Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	10.36 percent change	Standard Deviation 17.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	-8.06 percent change	Standard Deviation 19.7
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	7.31 percent change	Standard Deviation 18
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	16.76 percent change	Standard Deviation 25.1
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	6.92 percent change	Standard Deviation 9.1
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	1.01 percent change	Standard Deviation 16
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-0.34 percent change	Standard Deviation 25
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	-1.91 percent change	Standard Deviation 19
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	7.98 percent change	Standard Deviation 18.2
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	20.74 percent change	Standard Deviation 19.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	25.57 percent change	Standard Deviation 37
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	70.26 percent change	Standard Deviation 34
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	41.85 percent change	Standard Deviation 47.4
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	86.33 percent change	Standard Deviation 30.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	31.80 percent change	Standard Deviation 11
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	26.93 percent change	Standard Deviation 21.5
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	92.47 percent change	Standard Deviation 47.9
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	39.97 percent change	Standard Deviation 33.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	76.59 percent change	Standard Deviation 28.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	1.73 percent change	Standard Deviation 52.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-28.06 percent change	Standard Deviation 32.3
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	-6.44 percent change	Standard Deviation 38
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	69.43 percent change	Standard Deviation 75.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	7.07 percent change	Standard Deviation 33
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	9.86 percent change	Standard Deviation 41.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	117.56 percent change	Standard Deviation 52.4
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	22.68 percent change	Standard Deviation 24.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	-3.36 percent change	Standard Deviation 23.6
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	16.37 percent change	Standard Deviation 16.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	19.79 percent change	Standard Deviation 23.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	10.68 percent change	Standard Deviation 30.9
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	95.87 percent change	Standard Deviation 86.6
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-43.06 percent change	Standard Deviation 21.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	14.80 percent change	Standard Deviation 32.3
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	40.85 percent change	Standard Deviation 36.7
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	68.14 percent change	Standard Deviation 72.2
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	14.91 percent change	Standard Deviation 32.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	-8.75 percent change	Standard Deviation 46.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	40.38 percent change	Standard Deviation 34.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	38.65 percent change	Standard Deviation 36.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	42.59 percent change	Standard Deviation 59.2
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	60.99 percent change	Standard Deviation 151.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	17.58 percent change	Standard Deviation 42.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	78.60 percent change	Standard Deviation 94
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	10.74 percent change	Standard Deviation 37.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	9.67 percent change	Standard Deviation 49.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-20.03 percent change	Standard Deviation 44.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	45.94 percent change	Standard Deviation 114.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	44.08 percent change	Standard Deviation 61.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	57.94 percent change	Standard Deviation 91.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	116.93 percent change	Standard Deviation 215.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	15.64 percent change	Standard Deviation 32.3
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	31.87 percent change	Standard Deviation 86.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	-14.38 percent change	Standard Deviation 37.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	17.69 percent change	Standard Deviation 46.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	19.21 percent change	Standard Deviation 30.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	9.89 percent change	Standard Deviation 35.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-42.70 percent change	Standard Deviation 35
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	12.69 percent change	Standard Deviation 43.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	152.66 percent change	Standard Deviation 263.6
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD16/56	-4.09 percent change	Standard Deviation 34
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD16/56	-6.49 percent change	Standard Deviation 25.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD19	-16.04 percent change	Standard Deviation 33.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD8	-14.21 percent change	Standard Deviation 20.2
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD4	-5.88 percent change	Standard Deviation 23.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD4	-15.51 percent change	Standard Deviation 25.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD3	-7.20 percent change	Standard Deviation 20.7
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD8	-6.94 percent change	Standard Deviation 18.9
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 8 hr post dose on Day 14: CD19	2.53 percent change	Standard Deviation 36.2
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14	Change at 0 hr post dose on Day 14: CD3	-15.05 percent change	Standard Deviation 21.7

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18

Time frame: Baseline, Hour 0 on Day 18

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	16.98 percent change	Standard Deviation 50.8
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	13.89 percent change	Standard Deviation 27.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	17.52 percent change	Standard Deviation 32.7
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	11.58 percent change	Standard Deviation 31.5
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	12.44 percent change	Standard Deviation 29.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	-13.35 percent change	Standard Deviation 24.9
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	-15.78 percent change	Standard Deviation 15.9
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-7.64 percent change	Standard Deviation 73.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	-9.18 percent change	Standard Deviation 44.1
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	-14.04 percent change	Standard Deviation 30.6
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	-7.80 percent change	Standard Deviation 21.5
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	-10.24 percent change	Standard Deviation 21.3
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	-12.38 percent change	Standard Deviation 23.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-21.03 percent change	Standard Deviation 46
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	13.95 percent change	Standard Deviation 32.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	-18.76 percent change	Standard Deviation 24
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	-8.89 percent change	Standard Deviation 17.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	-10.65 percent change	Standard Deviation 18.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	22.65 percent change	Standard Deviation 45.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-48.63 percent change	Standard Deviation 63.5
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-17.13 percent change	Standard Deviation 45.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	-13.47 percent change	Standard Deviation 8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	-14.54 percent change	Standard Deviation 13.5
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	-8.14 percent change	Standard Deviation 35.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	-13.66 percent change	Standard Deviation 19.1
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	-29.44 percent change	Standard Deviation 25.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-76.21 percent change	Standard Deviation 28.2
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	-51.68 percent change	Standard Deviation 18.1
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	-46.69 percent change	Standard Deviation 17.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	-42.60 percent change	Standard Deviation 18.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD4	7.17 percent change	Standard Deviation 17.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD3	3.91 percent change	Standard Deviation 20
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD16/56	-0.68 percent change	Standard Deviation 22.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD19	-4.67 percent change	Standard Deviation 25.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18	Change at Day 18: CD8	4.70 percent change	Standard Deviation 15.9

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2

Time frame: Baseline, hr 0 on Day 2

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	18.27 percent change	Standard Deviation 30.4
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	8.88 percent change	Standard Deviation 24
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	7.58 percent change	Standard Deviation 40.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	12.67 percent change	Standard Deviation 19.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	8.58 percent change	Standard Deviation 26.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	9.56 percent change	Standard Deviation 30.5
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	61.26 percent change	Standard Deviation 47.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	32.68 percent change	Standard Deviation 30.1
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	34.74 percent change	Standard Deviation 27.4
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	33.29 percent change	Standard Deviation 25.4
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	17.40 percent change	Standard Deviation 24.5
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	19.68 percent change	Standard Deviation 29.3
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	26.73 percent change	Standard Deviation 31.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	23.93 percent change	Standard Deviation 31.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	52.84 percent change	Standard Deviation 54.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	46.07 percent change	Standard Deviation 31.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	63.21 percent change	Standard Deviation 45.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	44.17 percent change	Standard Deviation 33.9
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	30.39 percent change	Standard Deviation 11.3
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	43.04 percent change	Standard Deviation 29.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	0.61 percent change	Standard Deviation 37.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	14.05 percent change	Standard Deviation 24.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	16.96 percent change	Standard Deviation 25.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	18.85 percent change	Standard Deviation 34.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	7.04 percent change	Standard Deviation 33.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	103.79 percent change	Standard Deviation 45.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	52.43 percent change	Standard Deviation 34.3
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	50.97 percent change	Standard Deviation 30.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	55.80 percent change	Standard Deviation 35.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	45.72 percent change	Standard Deviation 44.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD8	-4.17 percent change	Standard Deviation 20.2
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD4	-6.85 percent change	Standard Deviation 18
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD3	-5.18 percent change	Standard Deviation 17.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD19	-4.22 percent change	Standard Deviation 24.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2	Change at Day 2: CD16/56	5.61 percent change	Standard Deviation 35.7

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21

Time frame: Baseline, hr 0 on Day 21

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-7.23 percent change	Standard Deviation 23.5
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-25.48 percent change	Standard Deviation 10.5
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-20.90 percent change	Standard Deviation 25.4
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-19.51 percent change	Standard Deviation 14
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-29.75 percent change	Standard Deviation 9.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-6.38 percent change	Standard Deviation 14.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-9.21 percent change	Standard Deviation 63.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-6.00 percent change	Standard Deviation 31.1
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-14.61 percent change	Standard Deviation 26.7
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-2.88 percent change	Standard Deviation 7.4
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-43.55 percent change	Standard Deviation 28.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-42.27 percent change	Standard Deviation 23.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-47.87 percent change	Standard Deviation 30.7
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-22.60 percent change	Standard Deviation 26.6
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-41.01 percent change	Standard Deviation 24.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-23.78 percent change	Standard Deviation 21.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-14.82 percent change	Standard Deviation 20.2
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-7.67 percent change	Standard Deviation 34.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-48.04 percent change	Standard Deviation 19
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-11.01 percent change	Standard Deviation 20.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-2.12 percent change	Standard Deviation 14.8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	5.62 percent change	Standard Deviation 35.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-17.50 percent change	Standard Deviation 27.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-7.93 percent change	Standard Deviation 13.5
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-9.41 percent change	Standard Deviation 16.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-27.37 percent change	Standard Deviation 13.3
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	-12.51 percent change	Standard Deviation 22.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-66.94 percent change	Standard Deviation 19.2
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-32.49 percent change	Standard Deviation 15.6
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	-22.38 percent change	Standard Deviation 13.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD8	-4.01 percent change	Standard Deviation 17.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD19	0.98 percent change	Standard Deviation 24.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD3	-1.12 percent change	Standard Deviation 17.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD16/56	-2.22 percent change	Standard Deviation 44.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21	Change at Day 21: CD4	1.16 percent change	Standard Deviation 19.8

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28

Time frame: Baseline, hr 0 on Day 28

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	-18.11 percent change	Standard Deviation 10
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	-21.29 percent change	Standard Deviation 13.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-11.96 percent change	Standard Deviation 9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	5.13 percent change	Standard Deviation 35.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	-7.96 percent change	Standard Deviation 24.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	9.29 percent change	Standard Deviation 24.5
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	11.58 percent change	Standard Deviation 18.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	21.29 percent change	Standard Deviation 23.5
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	21.93 percent change	Standard Deviation 51.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	10.97 percent change	Standard Deviation 29.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	1.02 percent change	Standard Deviation 35.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	1.96 percent change	Standard Deviation 42.3
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	0.38 percent change	Standard Deviation 34.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-2.84 percent change	Standard Deviation 35
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	-10.27 percent change	Standard Deviation 31.2
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	-28.52 percent change	Standard Deviation 51.6
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-9.33 percent change	Standard Deviation 18.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	-5.90 percent change	Standard Deviation 15.7
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	-6.53 percent change	Standard Deviation 21.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	-4.60 percent change	Standard Deviation 17.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	11.21 percent change	Standard Deviation 55.9
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	-16.50 percent change	Standard Deviation 28.3
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-6.13 percent change	Standard Deviation 21.8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	-7.60 percent change	Standard Deviation 23.3
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	-11.51 percent change	Standard Deviation 19.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	-19.90 percent change	Standard Deviation 6.3
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	-11.58 percent change	Standard Deviation 22.1
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-23.56 percent change	Standard Deviation 13.7
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	-22.08 percent change	Standard Deviation 9.7
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	-26.96 percent change	Standard Deviation 39.4
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD16/56	13.32 percent change	Standard Deviation 50.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD8	-1.56 percent change	Standard Deviation 26.7
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD19	-12.51 percent change	Standard Deviation 19.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD4	-2.86 percent change	Standard Deviation 24.9
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28	Change at Day 28: CD3	-2.57 percent change	Standard Deviation 25

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4

Time frame: Baseline, hr 0 on Day 4

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	-10.94 percent change	Standard Deviation 17.8
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	-15.87 percent change	Standard Deviation 22.4
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	-23.08 percent change	Standard Deviation 22.5
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	-12.59 percent change	Standard Deviation 27.2
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	-15.29 percent change	Standard Deviation 21.1
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	90.73 percent change	Standard Deviation 41.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	51.71 percent change	Standard Deviation 31.4
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	43.87 percent change	Standard Deviation 22
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	56.72 percent change	Standard Deviation 43.5
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	41.44 percent change	Standard Deviation 18.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	18.18 percent change	Standard Deviation 41.7
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	29.11 percent change	Standard Deviation 49
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	53.84 percent change	Standard Deviation 71.8
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	10.67 percent change	Standard Deviation 44.3
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	30.90 percent change	Standard Deviation 51.7
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	72.02 percent change	Standard Deviation 43.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	71.55 percent change	Standard Deviation 44.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	61.61 percent change	Standard Deviation 41.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	24.27 percent change	Standard Deviation 55.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	56.27 percent change	Standard Deviation 35.1
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	31.95 percent change	Standard Deviation 32.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	-5.23 percent change	Standard Deviation 43.2
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	42.50 percent change	Standard Deviation 56.7
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	34.28 percent change	Standard Deviation 41.8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	44.76 percent change	Standard Deviation 55.7
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	-1.66 percent change	Standard Deviation 44.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	77.25 percent change	Standard Deviation 50.7
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	29.81 percent change	Standard Deviation 33.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	39.46 percent change	Standard Deviation 27.2
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	32.81 percent change	Standard Deviation 28
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD8	-0.31 percent change	Standard Deviation 24.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD16/56	7.18 percent change	Standard Deviation 59.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD19	-2.55 percent change	Standard Deviation 37.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD4	6.08 percent change	Standard Deviation 31.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4	Change at Day 4: CD3	3.80 percent change	Standard Deviation 28.2

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42

Time frame: Baseline, hr 0 on Day 42

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	-12.74 percent change	Standard Deviation 29.1
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-31.86 percent change	Standard Deviation 30.9
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-25.65 percent change	Standard Deviation 30.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-20.79 percent change	Standard Deviation 29
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	-9.01 percent change	Standard Deviation 25.4
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	6.43 percent change	Standard Deviation 33.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	21.15 percent change	Standard Deviation 70.8
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-19.27 percent change	Standard Deviation 29.2
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	-10.04 percent change	Standard Deviation 37.2
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-15.72 percent change	Standard Deviation 29.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-9.39 percent change	Standard Deviation 29.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	-2.32 percent change	Standard Deviation 27.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	-12.93 percent change	Standard Deviation 33.9
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-11.58 percent change	Standard Deviation 30
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-11.42 percent change	Standard Deviation 30
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-1.60 percent change	Standard Deviation 19.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-4.08 percent change	Standard Deviation 17.5
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	-5.60 percent change	Standard Deviation 19.8
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	2.87 percent change	Standard Deviation 76.1
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-10.22 percent change	Standard Deviation 27.3
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	24.08 percent change	Standard Deviation 35.8
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-20.20 percent change	Standard Deviation 30
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-12.27 percent change	Standard Deviation 24.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	-3.24 percent change	Standard Deviation 17.6
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-9.17 percent change	Standard Deviation 21.5
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	-3.81 percent change	Standard Deviation 12
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	4.19 percent change	Standard Deviation 31.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	-4.54 percent change	Standard Deviation 37.4
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	-1.63 percent change	Standard Deviation 20.2
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-8.30 percent change	Standard Deviation 16.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD16/56	19.90 percent change	Standard Deviation 41.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD4	0.96 percent change	Standard Deviation 35.7
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD3	0.19 percent change	Standard Deviation 32.6
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD8	3.57 percent change	Standard Deviation 33.5
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42	Change at Day 42: CD19	-3.93 percent change	Standard Deviation 52.5

Primary

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7

Time frame: Baseline, hr 0 on Day 7

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	6.52 percent change	Standard Deviation 22.6
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	5.72 percent change	Standard Deviation 20.6
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	-10.57 percent change	Standard Deviation 14.3
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	6.76 percent change	Standard Deviation 18.5
CP-690,550 5 mg (Cohort 1)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	13.01 percent change	Standard Deviation 36.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	31.50 percent change	Standard Deviation 42.3
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	34.47 percent change	Standard Deviation 24.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	29.97 percent change	Standard Deviation 56.6
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	28.15 percent change	Standard Deviation 26
CP-690,550 10 mg (Cohort 2)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	29.39 percent change	Standard Deviation 22.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	7.21 percent change	Standard Deviation 50.1
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	13.47 percent change	Standard Deviation 55.4
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	17.02 percent change	Standard Deviation 83
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	55.54 percent change	Standard Deviation 83.2
CP-690,550 20 mg (Cohort 3)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	14.99 percent change	Standard Deviation 56.6
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	25.51 percent change	Standard Deviation 38.9
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	24.48 percent change	Standard Deviation 39.3
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	72.86 percent change	Standard Deviation 67.4
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	-1.43 percent change	Standard Deviation 40
CP-690,550 30 mg (Cohort 4)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	21.74 percent change	Standard Deviation 37.5
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	1.61 percent change	Standard Deviation 26
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	-2.37 percent change	Standard Deviation 56.4
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	1.74 percent change	Standard Deviation 25.2
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	15.14 percent change	Standard Deviation 46
CP-690,550 60 mg (Cohort 5)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	0.91 percent change	Standard Deviation 26.6
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	30.95 percent change	Standard Deviation 27.8
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	98.64 percent change	Standard Deviation 102.9
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	-7.95 percent change	Standard Deviation 30.2
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	34.77 percent change	Standard Deviation 33.1
CP-690,550 50 mg (Cohort 6)	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	37.42 percent change	Standard Deviation 33.1
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD3	-3.08 percent change	Standard Deviation 17.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD8	-3.10 percent change	Standard Deviation 19.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD19	-2.40 percent change	Standard Deviation 22.3
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD4	-3.28 percent change	Standard Deviation 17.8
Placebo	Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7	Change at Day 7: CD16/56	2.26 percent change	Standard Deviation 35.2

Primary

Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function

Time frame: Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42

Population: Data was not analyzed as per planned analyses due to pattern of changes observed.

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Cohort 1)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	0.50 hr
CP-690,550 10 mg (Cohort 2)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	0.50 hr
CP-690,550 20 mg (Cohort 3)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	0.50 hr
CP-690,550 30 mg (Cohort 4)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	0.50 hr
CP-690,550 60 mg (Cohort 5)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	1.00 hr
CP-690,550 50 mg (Cohort 6)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1	1.00 hr

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Cohort 1)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	0.50 hr
CP-690,550 10 mg (Cohort 2)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	1.00 hr
CP-690,550 20 mg (Cohort 3)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	0.50 hr
CP-690,550 30 mg (Cohort 4)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	1.00 hr
CP-690,550 60 mg (Cohort 5)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	1.00 hr
CP-690,550 50 mg (Cohort 6)	Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14	1.00 hr

Secondary

Gene Expression in Peripheral Blood

Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).

Time frame: Day 14

Population: Analysis population:all participants who met eligibility criteria. 'N'(number of participants analyzed)=participants evaluable for this measure. 'n =participants evaluable for specified category for each arm group respectively. Gene expression results were planned to be analyzed for participants who received CP-690,550 5,30 mg and matching placebo.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	BAX (n=9,9,6)	1.10 relative expression unit (REU)	Standard Deviation 0.32
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	IFN-gamma (n=9,9,6)	2.06 relative expression unit (REU)	Standard Deviation 1.58
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	CD 25 (n=9,9,6)	1.19 relative expression unit (REU)	Standard Deviation 0.5
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	TNF-FasL (n=9,9,6)	0.99 relative expression unit (REU)	Standard Deviation 0.37
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	TNF-SF5 (n=9,9,6)	1.79 relative expression unit (REU)	Standard Deviation 1.14
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	iNOS (n=2,1,1)	77.79 relative expression unit (REU)	Standard Deviation 40.1
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	BCL2 (n=9,9,6)	0.71 relative expression unit (REU)	Standard Deviation 0.4
CP-690,550 5 mg (Cohort 1)	Gene Expression in Peripheral Blood	Granzyme B (n=9,9,6)	0.69 relative expression unit (REU)	Standard Deviation 0.33
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	BCL2 (n=9,9,6)	0.90 relative expression unit (REU)	Standard Deviation 0.3
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	BAX (n=9,9,6)	0.98 relative expression unit (REU)	Standard Deviation 0.25
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	iNOS (n=2,1,1)	0.97 relative expression unit (REU)	Standard Deviation 0.08
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	CD 25 (n=9,9,6)	1.02 relative expression unit (REU)	Standard Deviation 0.29
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	Granzyme B (n=9,9,6)	0.99 relative expression unit (REU)	Standard Deviation 0.58
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	IFN-gamma (n=9,9,6)	1.16 relative expression unit (REU)	Standard Deviation 0.59
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	TNF-SF5 (n=9,9,6)	1.29 relative expression unit (REU)	Standard Deviation 0.48
CP-690,550 10 mg (Cohort 2)	Gene Expression in Peripheral Blood	TNF-FasL (n=9,9,6)	1.09 relative expression unit (REU)	Standard Deviation 0.53
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	CD 25 (n=9,9,6)	1.01 relative expression unit (REU)	Standard Deviation 0.24
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	TNF-FasL (n=9,9,6)	1.27 relative expression unit (REU)	Standard Deviation 0.83
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	BAX (n=9,9,6)	0.97 relative expression unit (REU)	Standard Deviation 0.22
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	IFN-gamma (n=9,9,6)	1.46 relative expression unit (REU)	Standard Deviation 0.86
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	TNF-SF5 (n=9,9,6)	1.24 relative expression unit (REU)	Standard Deviation 0.38
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	BCL2 (n=9,9,6)	1.01 relative expression unit (REU)	Standard Deviation 0.22
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	iNOS (n=2,1,1)	0.02 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Peripheral Blood	Granzyme B (n=9,9,6)	1.58 relative expression unit (REU)	Standard Deviation 1.13

Secondary

Gene Expression in Psoriatic Plaque Biopsies

Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.

Time frame: Day 14

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	Perforin	2.80 relative expression unit (REU)	Standard Deviation 2.56
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	PCNA	2.09 relative expression unit (REU)	Standard Deviation 0.77
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	CD25	7.34 relative expression unit (REU)	Standard Deviation 2.33
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	IL-2	0.98 relative expression unit (REU)	Standard Deviation 0.16
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	CXCL10	15.03 relative expression unit (REU)	Standard Deviation 5.75
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	BCL-2	0.47 relative expression unit (REU)	Standard Deviation 0.09
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	IL-8	556.12 relative expression unit (REU)	Standard Deviation 754.91
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	TNF-FasL	0.95 relative expression unit (REU)	Standard Deviation 0.24
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	K-16	69.04 relative expression unit (REU)	Standard Deviation 7.6
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	Granzyme B	42.71 relative expression unit (REU)	Standard Deviation 18.54
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	INF-gamma	2.26 relative expression unit (REU)	Standard Deviation 1.49
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	INOS	77.79 relative expression unit (REU)	Standard Deviation 40.1
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	BAX	1.16 relative expression unit (REU)	Standard Deviation 0.21
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	IL-15	0.51 relative expression unit (REU)	Standard Deviation 0.01
CP-690,550 5 mg (Cohort 1)	Gene Expression in Psoriatic Plaque Biopsies	IL-7	0.85 relative expression unit (REU)	Standard Deviation 0.11
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	IL-15	0.70 relative expression unit (REU)	Standard Deviation 0.06
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	IL-7	1.26 relative expression unit (REU)	Standard Deviation 0.51
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	BAX	0.83 relative expression unit (REU)	Standard Deviation 0.28
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	K-16	5.18 relative expression unit (REU)	Standard Deviation 2.63
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	CD25	1.05 relative expression unit (REU)	Standard Deviation 0.27
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	PCNA	1.15 relative expression unit (REU)	Standard Deviation 0.06
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	Perforin	0.65 relative expression unit (REU)	Standard Deviation 0.17
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	TNF-FasL	1.24 relative expression unit (REU)	Standard Deviation 0.86
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	CXCL10	0.44 relative expression unit (REU)	Standard Deviation 0.45
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	INOS	0.97 relative expression unit (REU)	Standard Deviation 0.08
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	Granzyme B	1.20 relative expression unit (REU)	Standard Deviation 0.07
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	IL-2	0.87 relative expression unit (REU)	Standard Deviation 0.02
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	IL-8	14.66 relative expression unit (REU)	—
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	BCL-2	0.36 relative expression unit (REU)	Standard Deviation 0.14
CP-690,550 10 mg (Cohort 2)	Gene Expression in Psoriatic Plaque Biopsies	INF-gamma	0.90 relative expression unit (REU)	Standard Deviation 0.09
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	INF-gamma	0.22 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	IL-15	0.86 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	BCL-2	2.29 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	CD25	0.16 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	CXCL10	0.04 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	Granzyme B	0.03 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	IL-2	0.75 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	IL-8	0.00 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	INOS	0.02 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	BAX	0.68 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	IL-7	1.19 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	K-16	0.04 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	PCNA	0.41 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	Perforin	0.23 relative expression unit (REU)	—
CP-690,550 20 mg (Cohort 3)	Gene Expression in Psoriatic Plaque Biopsies	TNF-FasL	0.64 relative expression unit (REU)	—

Secondary

Immunohistochemistry From Psoriatic Plaque Biopsies

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.

Time frame: Baseline (within 7 days prior to Day 1), Day 14

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 epidermal (n=1,1,4,2)	148.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 dermal (n=1,1,4,2)	26.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 epidermal (n=1,1,4,2)	85.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 dermal (n=1,1,4,2)	120.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 epidermal (n=1,1,4,2)	115.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 dermal (n=1,1,4,2)	189.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 dermal (n=1,1,4,2)	11.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 epidermal (n=1,1,4,2)	42.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 dermal (n=1,1,4,2)	23.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 epidermal (n=1,1,4,2)	13.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 epidermal (n=1,1,4,2)	66.00 cells/microliter (cells/μL)	—
CP-690,550 5 mg (Cohort 1)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 dermal (n=1,1,4,2)	27.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 dermal (n=1,1,4,2)	42.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 epidermal (n=1,1,4,2)	56.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 epidermal (n=1,1,4,2)	11.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 epidermal (n=1,1,4,2)	96.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 epidermal (n=1,1,4,2)	55.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 dermal (n=1,1,4,2)	17.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 epidermal (n=1,1,4,2)	44.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 dermal (n=1,1,4,2)	114.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 dermal (n=1,1,4,2)	78.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 epidermal (n=1,1,4,2)	108.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 dermal (n=1,1,4,2)	53.00 cells/microliter (cells/μL)	—
CP-690,550 10 mg (Cohort 2)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 dermal (n=1,1,4,2)	135.00 cells/microliter (cells/μL)	—
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 dermal (n=1,1,4,2)	130.00 cells/microliter (cells/μL)	Standard Deviation 81.3
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 dermal (n=1,1,4,2)	123.75 cells/microliter (cells/μL)	Standard Deviation 103.6
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 dermal (n=1,1,4,2)	90.50 cells/microliter (cells/μL)	Standard Deviation 54.4
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 dermal (n=1,1,4,2)	3.25 cells/microliter (cells/μL)	Standard Deviation 2.2
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 epidermal (n=1,1,4,2)	122.50 cells/microliter (cells/μL)	Standard Deviation 50.8
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 epidermal (n=1,1,4,2)	108.50 cells/microliter (cells/μL)	Standard Deviation 40.9
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 epidermal (n=1,1,4,2)	17.00 cells/microliter (cells/μL)	Standard Deviation 12.1
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 dermal (n=1,1,4,2)	18.00 cells/microliter (cells/μL)	Standard Deviation 7.3
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 epidermal (n=1,1,4,2)	82.25 cells/microliter (cells/μL)	Standard Deviation 121
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 dermal (n=1,1,4,2)	95.25 cells/microliter (cells/μL)	Standard Deviation 59.4
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 epidermal (n=1,1,4,2)	51.50 cells/microliter (cells/μL)	Standard Deviation 50.8
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 epidermal (n=1,1,4,2)	1.25 cells/microliter (cells/μL)	Standard Deviation 1.5
CP-690,550 20 mg (Cohort 3)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 dermal (n=1,1,4,2)	3.00 cells/microliter (cells/μL)	Standard Deviation 0
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 epidermal (n=1,1,4,2)	41.50 cells/microliter (cells/μL)	Standard Deviation 34.6
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD83 epidermal (n=1,1,4,2)	1.50 cells/microliter (cells/μL)	Standard Deviation 0.7
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 dermal (n=1,1,4,2)	74.00 cells/microliter (cells/μL)	Standard Deviation 70.7
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD8 dermal (n=1,1,4,2)	25.00 cells/microliter (cells/μL)	Standard Deviation 9.9
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD8 epidermal (n=1,1,4,2)	71.50 cells/microliter (cells/μL)	Standard Deviation 19.1
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 dermal (n=1,1,4,2)	196.00 cells/microliter (cells/μL)	Standard Deviation 99
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: CD3 epidermal (n=1,1,4,2)	124.50 cells/microliter (cells/μL)	Standard Deviation 55.9
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 epidermal (n=1,1,4,2)	7.00 cells/microliter (cells/μL)	Standard Deviation 9.9
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD83 dermal (n=1,1,4,2)	9.50 cells/microliter (cells/μL)	Standard Deviation 9.2
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 dermal (n=1,1,4,2)	92.00 cells/microliter (cells/μL)	Standard Deviation 53.7
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Day 14: CD3 epidermal (n=1,1,4,2)	97.00 cells/microliter (cells/μL)	Standard Deviation 41
CP-690,550 30 mg (Cohort 4)	Immunohistochemistry From Psoriatic Plaque Biopsies	Baseline: Absolute CD16/56 (n=0,0,0,0)	NA cells/microliter (cells/μL)	—

Secondary

Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.

Time frame: Baseline (within 7 days prior to Day 1) up to Day 14

Population: Analysis of ICAM-1 in biopsy specimens was not performed as it often continues to be expressed on vessels in the skin even when psoriasis was resolved, thus would not provide a measure of response to therapy.

Secondary

Number of Participants With Keratin 16 (K16) Expression

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.

Time frame: Baseline (within 7 days prior to Day 1) up to Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Number of Participants With Keratin 16 (K16) Expression	Baseline	1 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Keratin 16 (K16) Expression	Day 14	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Keratin 16 (K16) Expression	Day 14	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Keratin 16 (K16) Expression	Baseline	1 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Keratin 16 (K16) Expression	Day 14	4 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Keratin 16 (K16) Expression	Baseline	4 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Keratin 16 (K16) Expression	Baseline	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Keratin 16 (K16) Expression	Day 14	2 participants

Secondary

Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14

Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.

Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	2 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	3 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	2 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	3 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	1 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	1 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	1 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	2 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	3 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	2 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	4 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	2 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	8 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	1 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	3 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	5 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	1 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	1 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	6 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	2 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	7 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	3 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	7 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	4 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	2 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	6 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	4 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	3 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	4 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	1 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	3 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	2 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	2 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	2 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	5 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	4 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	2 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	1 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	4 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	6 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 2	4 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 0	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 0	1 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 3	1 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 4	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 4	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 3	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 2	9 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 3	1 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 2	9 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 1	8 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Erythema: 1	4 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 0	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Scaling: 4	0 participants
Placebo	Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14	Induration: 1	2 participants

Secondary

Number of Participants With Physician's Global Assessment (PGA) of Psoriasis

Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).

Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14

Population: Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	3 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	1 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	0 participants
CP-690,550 5 mg (Cohort 1)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	3 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	1 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	0 participants
CP-690,550 10 mg (Cohort 2)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	3 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	2 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	2 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	0 participants
CP-690,550 20 mg (Cohort 3)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	2 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	0 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	1 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	4 participants
CP-690,550 30 mg (Cohort 4)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	1 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	3 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	1 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 60 mg (Cohort 5)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	4 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	4 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	2 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	0 participants
CP-690,550 50 mg (Cohort 6)	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	2 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:5	5 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:4	2 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:3	5 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:2	1 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:1	0 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:7	0 participants
Placebo	Number of Participants With Physician's Global Assessment (PGA) of Psoriasis	PGA:6	1 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Accumulation Ratio (R0)

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14

Change From Baseline in Immune Cell Function at Day 14

Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14

Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1

Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14

Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1

Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1

Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14

Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1

Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14

Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1

Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14

Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1

Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14

Change From Baseline in Reticulocyte Count at Day 10

Change From Baseline in Reticulocyte Count at Day 15

Change From Baseline in Reticulocyte Count at Day 2

Change From Baseline in Reticulocyte Count at Day 21

Change From Baseline in Reticulocyte Count at Day 28

Change From Baseline in Reticulocyte Count at Day 4

Change From Baseline in Reticulocyte Count at Day 42

Change From Baseline in Reticulocyte Count at Day 7

Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)

Maximum Observed Plasma Concentration (Cmax) at Day 1

Maximum Observed Plasma Concentration (Cmax) at Day 14

Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond

Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42

Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7

Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function

Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1

Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14

Gene Expression in Peripheral Blood

Gene Expression in Psoriatic Plaque Biopsies

Immunohistochemistry From Psoriatic Plaque Biopsies

Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression

Number of Participants With Keratin 16 (K16) Expression

Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14

Number of Participants With Physician's Global Assessment (PGA) of Psoriasis